Den europeiske union - norsk - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - influensa, human - antivirale midler til systemisk bruk - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukemi, lymfocytisk, kronisk, b-celle - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Den europeiske union - norsk - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glykogen storage sykdom type ii - andre alimentary tract and metabolism products, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiske midler - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den europeiske union - norsk - EMA (European Medicines Agency)

lipomed gmbh - deferiprone - iron overload; beta-thalassemia - alle andre terapeutiske produkter - deferiprone lipomed monoterapi er indisert for behandling av jern overbelastning hos pasienter med thalassaemia store når nåværende chelation terapi er kontraindisert eller utilstrekkelig. deferiprone lipomed i kombinasjon med annen chelator er indisert hos pasienter med thalassaemia store når monoterapi med jern chelator er ineffektiv, eller når det gjelder forebygging eller behandling av livstruende konsekvenser av jern overbelastning rettferdiggjør rask eller intensiv korreksjon.

Den europeiske union - norsk - EMA (European Medicines Agency)

sanofi b.v. - agalsidase beta - fabry sykdom - andre alimentary tract and metabolism products, - fabrazyme er indisert for langsiktig enzymutskiftningsterapi hos pasienter med en bekreftet diagnose av fabrys sykdom (a-galaktosidase-a-mangel).

Den europeiske union - norsk - EMA (European Medicines Agency)

mylan pharmaceuticals limited - zonisamid - epilepsi - antiepileptics, - monoterapi i behandling av partielle anfall med eller uten sekundær generalisering, i voksne med nylig diagnostisert epilepsi;tilleggsbehandling ved behandling av partielle anfall med eller uten sekundær generalisering, i voksne, ungdom og barn i alderen 6 år og oppover.

Norge - norsk - Statens legemiddelverk

casen recordati, s.l - dinatriumfosfatdodekahydrat / natriumdihydrogenfosfatdihydrat - mikstur, oppløsning - 10.8 g/ dose / 24.4 g/ dose